D.E. Shaw & Co
SRPT icon

D.E. Shaw & Co’s Sarepta Therapeutics SRPT Stock Holding History

D.E. Shaw & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
+10,000
New +$189K ﹤0.01% 4573
2023
Q1 		– Sell
-10,000
Closed -$1.3M – 4838
2022
Q4 		$1.3M Hold
10,000
– – ﹤0.01% 3261
2022
Q3 		$1.1M Buy
+10,000
New +$1.01M ﹤0.01% 3520
2021
Q1 		– Sell
-10,000
Closed -$1.71M – 4458
2020
Q4 		$1.71M Hold
10,000
– – ﹤0.01% 2653
2020
Q3 		$1.4M Hold
10,000
– – ﹤0.01% 2633
2020
Q2 		$1.6M Sell
10,000
-2,000
-17% -$272K ﹤0.01% 2580
2020
Q1 		$1.17M Sell
12,000
-57,700
-83% -$6.6M ﹤0.01% 2613
2019
Q4 		$8.99M Sell
69,700
-1,400
-2% -$141K 0.01% 1271
2019
Q3 		$5.36M Buy
71,100
+10,000
+16% +$1.18M 0.01% 1596
2019
Q2 		$9.28M Sell
61,100
-20,000
-25% -$2.43M 0.01% 1173
2019
Q1 		$9.67M Sell
81,100
-65,000
-44% -$8.36M 0.01% 1128
2018
Q4 		$15.9M Buy
146,100
+10,000
+7% +$1.25M 0.02% 807
2018
Q3 		$22M Buy
136,100
+40,900
+43% +$5.59M 0.03% 735
2018
Q2 		$12.6M Buy
95,200
+35,200
+59% +$3.32M 0.02% 963
2018
Q1 		$4.45M Buy
60,000
+3,500
+6% +$233K 0.01% 1490
2017
Q4 		$3.14M Buy
56,500
+10,000
+22% +$530K ﹤0.01% 1815
2017
Q3 		$2.11M Hold
46,500
– – ﹤0.01% 1983
2017
Q2 		$1.57M Hold
46,500
– – ﹤0.01% 2131
2017
Q1 		$1.38M Sell
46,500
-20,000
-30% -$619K ﹤0.01% 2089
2016
Q4 		$1.82M Buy
66,500
+26,500
+66% +$1.06M ﹤0.01% 2059
2016
Q3 		$2.46M Hold
40,000
– – ﹤0.01% 1767
2016
Q2 		$763K Hold
40,000
– – ﹤0.01% 2571
2016
Q1 		$781K Buy
40,000
+30,000
+300% +$524K ﹤0.01% 2523
2015
Q4 		$386K Buy
+10,000
New +$324K ﹤0.01% 3239
2014
Q3 		– Sell
-12,500
Closed -$372K – 4374
2014
Q2 		$372K Buy
+12,500
New +$395K ﹤0.01% 3723

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

D.E. Shaw & Co's SRPT Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 474,986 shares — an estimated $8.98M sold.

D.E. Shaw & Co first reported a position in SRPT in Q2 2013 and held it in 47 quarters. The position peaked at $117M in Q1 2023. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • D.E. Shaw & Co reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 474,986 Sarepta Therapeutics shares in Q2 2026, an estimated $8.98M.
  • D.E. Shaw & Co first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 47 quarters.
  • D.E. Shaw & Co's Sarepta Therapeutics position peaked at $117M in Q1 2023.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.